Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million
Insilico Medicine, a Hong Kong-based AI-driven drug discovery company that intends to list in Hong Kong after it unveiled an initial public offering plan (IPO) last year, has sold its …